The Experts below are selected from a list of 61974 Experts worldwide ranked by ideXlab platform
Martin Andersson - One of the best experts on this subject based on the ideXlab platform.
-
acquisitions of start ups by incumbent businesses a market selection Process of high quality entrants
Research Policy, 2016Co-Authors: Martin Andersson, Jing XiaoAbstract:We analyze the frequency and nature by which new firms are acquired by established businesses. Acquisitions are often considered to reflect a Technology Transfer Process and to also constitute one way in which a "symbiosis" between new Technology-based firms (NTBFs) and established businesses is realized. Using a micro-level dataset for Sweden in which we follow new entrants up to 18 years after entry, we show that acquisitions of recent start-ups are rare and restricted to a small group of entrants with defining characteristics. Estimates from competing risks models show that acquired start-ups, in particular by multinational enterprises (MNEs), stand out from entrants that either remain independent or exit by being much more likely to be spin-offs operating in high-tech sectors, having strong technological competence, and having weak internal financial resources. Our overall findings support the argument that acquisitions primarily concern NTBFs in market contexts where entry costs are large, access to finance is important and incumbents have valuable complementary capabilities and resources. (C) 2015 Elsevier B.V. All rights reserved.
-
acquisitions of start ups by incumbent businesses a market selection Process of high quality entrants
Research Papers in Economics, 2014Co-Authors: Martin Andersson, Jing XiaoAbstract:We analyze the frequency and nature by which new firms are acquired by established businesses. Acquisitions are often considered to reflect a Technology Transfer Process and to also constitute one way in which a “symbiosis” between new Technology-based firms (NTBFs) and established businesses is realized. Using a micro-level dataset for Sweden in which we follow new entrants up to 18 years after entry, we show that acquisitions of recent start-ups are rare and restricted to a small group of entrants with defining characteristics. Estimates from competing risks models show that acquired start-ups, in particular by multinational enterprises (MNEs), stand out from entrants that either remain independent or exit by being much more likely to be spin-offs operating in high-tech sectors, having strong technological competence, and having weak internal financial resources. Our overall findings support the argument that acquisitions primarily concern NTBFs in market contexts where entry costs are large, access to finance is important and incumbents have high market power.
Jing Xiao - One of the best experts on this subject based on the ideXlab platform.
-
acquisitions of start ups by incumbent businesses a market selection Process of high quality entrants
Research Policy, 2016Co-Authors: Martin Andersson, Jing XiaoAbstract:We analyze the frequency and nature by which new firms are acquired by established businesses. Acquisitions are often considered to reflect a Technology Transfer Process and to also constitute one way in which a "symbiosis" between new Technology-based firms (NTBFs) and established businesses is realized. Using a micro-level dataset for Sweden in which we follow new entrants up to 18 years after entry, we show that acquisitions of recent start-ups are rare and restricted to a small group of entrants with defining characteristics. Estimates from competing risks models show that acquired start-ups, in particular by multinational enterprises (MNEs), stand out from entrants that either remain independent or exit by being much more likely to be spin-offs operating in high-tech sectors, having strong technological competence, and having weak internal financial resources. Our overall findings support the argument that acquisitions primarily concern NTBFs in market contexts where entry costs are large, access to finance is important and incumbents have valuable complementary capabilities and resources. (C) 2015 Elsevier B.V. All rights reserved.
-
acquisitions of start ups by incumbent businesses a market selection Process of high quality entrants
Research Papers in Economics, 2014Co-Authors: Martin Andersson, Jing XiaoAbstract:We analyze the frequency and nature by which new firms are acquired by established businesses. Acquisitions are often considered to reflect a Technology Transfer Process and to also constitute one way in which a “symbiosis” between new Technology-based firms (NTBFs) and established businesses is realized. Using a micro-level dataset for Sweden in which we follow new entrants up to 18 years after entry, we show that acquisitions of recent start-ups are rare and restricted to a small group of entrants with defining characteristics. Estimates from competing risks models show that acquired start-ups, in particular by multinational enterprises (MNEs), stand out from entrants that either remain independent or exit by being much more likely to be spin-offs operating in high-tech sectors, having strong technological competence, and having weak internal financial resources. Our overall findings support the argument that acquisitions primarily concern NTBFs in market contexts where entry costs are large, access to finance is important and incumbents have high market power.
Helen Mcshane - One of the best experts on this subject based on the ideXlab platform.
-
Assay optimisation and Technology Transfer for multi-site immuno-monitoring in vaccine trials.
PloS one, 2017Co-Authors: Steven G. Smith, Iman Satti, Hazel M. Dockrell, Stephanie A. Harris, Donna Bryan, K. Barry Walker, Helen McshaneAbstract:Cellular immunological assays are important tools for the monitoring of responses to T-cell-inducing vaccine candidates. As these bioassays are often technically complex and require considerable experience, careful Technology Transfer between laboratories is critical if high quality, reproducible data that allows comparison between sites, is to be generated. The aim of this study, funded by the European Union Framework Program 7-funded TRANSVAC project, was to optimise Standard Operating Procedures and the Technology Transfer Process to maximise the reproducibility of three bioassays for interferon-gamma responses: enzyme-linked immunosorbent assay (ELISA), ex-vivo enzyme-linked immunospot and intracellular cytokine staining. We found that the initial variability in results generated across three different laboratories reduced following a combination of Standard Operating Procedure harmonisation and the undertaking of side-by-side training sessions in which assay operators performed each assay in the presence of an assay 'lead' operator. Mean inter-site coefficients of variance reduced following this training session when compared with the pre-training values, most notably for the ELISA assay. There was a trend for increased inter-site variability at lower response magnitudes for the ELISA and intracellular cytokine staining assays. In conclusion, we recommend that on-site operator training is an essential component of the assay Technology Transfer Process and combined with harmonised Standard Operating Procedures will improve the quality, reproducibility and comparability of data produced across different laboratories. These data may be helpful in ongoing discussions of the potential risk/benefit of centralised immunological assay strategies for large clinical trials versus decentralised units.
Detelin S Elenkov - One of the best experts on this subject based on the ideXlab platform.
-
linking international Technology Transfer with strategy and management a literature commentary
Research Policy, 1994Co-Authors: Michael A Cusumano, Detelin S ElenkovAbstract:Abstract This article represents an attempt to link literature from diverse but fundamentally related areas: research on international Technology Transfer as well as on Technology strategy and management. It argues that these literatures need to be linked because both treat problems inherent to managing Technology development that must succeed at the level of the firm, not the level of the nation state or government facilities. The discussion here focuses on issues that frequently appear in recent writings on international Technology Transfer: the relationship between international Technology Transfer and cultivation of indigenous capabilities within the Technology recipients; organizational options and their effectiveness for international Technology Transfer; the influence of external factors on the outcomes of international Technology Transfer Process for Technology recipients; and policies of host-country governments concerning Transfer of foreign Technology. We examine these issues from the viewpoints of both international Technology Transfer and Technology strategy and management. The objective is to identify perspectives from research on Technology strategy and management that might help solve basic problems in international Technology Transfer.
Steven G. Smith - One of the best experts on this subject based on the ideXlab platform.
-
Assay optimisation and Technology Transfer for multi-site immuno-monitoring in vaccine trials.
PloS one, 2017Co-Authors: Steven G. Smith, Iman Satti, Hazel M. Dockrell, Stephanie A. Harris, Donna Bryan, K. Barry Walker, Helen McshaneAbstract:Cellular immunological assays are important tools for the monitoring of responses to T-cell-inducing vaccine candidates. As these bioassays are often technically complex and require considerable experience, careful Technology Transfer between laboratories is critical if high quality, reproducible data that allows comparison between sites, is to be generated. The aim of this study, funded by the European Union Framework Program 7-funded TRANSVAC project, was to optimise Standard Operating Procedures and the Technology Transfer Process to maximise the reproducibility of three bioassays for interferon-gamma responses: enzyme-linked immunosorbent assay (ELISA), ex-vivo enzyme-linked immunospot and intracellular cytokine staining. We found that the initial variability in results generated across three different laboratories reduced following a combination of Standard Operating Procedure harmonisation and the undertaking of side-by-side training sessions in which assay operators performed each assay in the presence of an assay 'lead' operator. Mean inter-site coefficients of variance reduced following this training session when compared with the pre-training values, most notably for the ELISA assay. There was a trend for increased inter-site variability at lower response magnitudes for the ELISA and intracellular cytokine staining assays. In conclusion, we recommend that on-site operator training is an essential component of the assay Technology Transfer Process and combined with harmonised Standard Operating Procedures will improve the quality, reproducibility and comparability of data produced across different laboratories. These data may be helpful in ongoing discussions of the potential risk/benefit of centralised immunological assay strategies for large clinical trials versus decentralised units.
